An interventional study of brimonidine tartrate/timolol fixed combination ophthalmic solution and brimonidine tartrate ophthalmic solution in Glaucoma and Ocular Hypertension, sponsored by Allergan. Completed at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2012-09-14.
Sponsored by Allergan (part of AbbVie) · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies testing brimonidine in Glaucoma — 1 open to participants now, 1 under way, none of them phase 3. brimonidine · Glaucoma.
Among the 23 studies testing brimonidine in Glaucoma, this one is the 3rd largest by enrollment of the 21 interventional ones that give a count, is one of 2 that started in 2010, is one of 7 with no phase, and was the 16th registered.
1,419 studies on the registry are indexed under Glaucoma; 221 are open to participants now.
Browse Glaucoma studies →1 of the 23 studies testing brimonidine in Glaucoma is open now, in 1 country. Recruiting first, the newest first:
Tulane University · Sites in United States
Ages 18+
By country, each count listing its studies:
brimonidine: first FDA approval 1996 (ALPHAGAN), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 155 Glaucoma studies recruiting now, 113 (73%) set no upper age limit and 9 (6%) stop at 75 or younger; 13 take children under 18; 44 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
First in 1999; this study’s year is marked. 2 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 238 is above the median of 61 across 964 interventional studies indexed under Glaucoma.
Median enrollment 56 across the 21 interventional studies. Of the 18 that completed or were terminated, 6 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 23 have an industry lead sponsor. The 10 most frequent:
This study is registered under Allergan, one of the names counted as AbbVie. Under that name alone:
Allergan is the lead sponsor of 505 studies on the registry; none are open to participants now.
Of its 93 completed or terminated interventional studies of FDA-regulated products, 91 (98%) have results posted.
34 studies in Glaucoma by AbbVie: none open now, none under way, none of them phase 3. Of 33 finished, 23 (70%) have results posted.
Among the 34 studies in Glaucoma by AbbVie, this one is the 11th largest by enrollment of the 31 interventional ones that give a count, is one of 4 that started in 2010, is the only one with no phase, and was the 19th registered.
AbbVie’s Glaucoma studies by the year they started, since 2002.
None of the studies under way reaches primary completion within a year.
Among the 23 studies testing brimonidine in Glaucoma, from their registry updates:
Among AbbVie’s 34 in Glaucoma:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will evaluate the safety and efficacy of brimonidine tartrate/timolol fixed combination (Combigan®) compared with brimonidine tartrate (Alphagan®) and timolol in patients with glaucoma or ocular hypertension who do not respond well to topical beta blockers.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
One drop of brimonidine tartrate/timolol combination ophthalmic solution (Combigan®) and one drop of brimonidine tartrate/timolol fixed combination vehicle administered to the affected eye(s) twice daily (morning and evening) for four weeks.
Drug: brimonidine tartrate/timolol fixed combination ophthalmic solution · Other: fixed combination vehicle
One drop of brimonidine tartrate ophthalmic solution (Alphagan®) and one drop of timolol ophthalmic solution administered to the affected eye(s) twice daily (morning and evening) for four weeks.
Drug: brimonidine tartrate ophthalmic solution · Drug: timolol ophthalmic solution
One drop of brimonidine tartrate/timolol fixed combination ophthalmic solution (Combigan®) administered to the affected eye(s) twice daily (morning and evening) for four weeks.
Also known as: Combigan®
One drop of brimonidine tartrate ophthalmic solution (Alphagan®) administered to the affected eye(s) twice daily (morning and evening) for four weeks.
Also known as: Alphagan®
One drop of timolol ophthalmic solution administered to the affected eye(s) twice daily (morning and evening) for four weeks.
Fixed combination vehicle administered to the affected eye(s) twice daily (morning and evening) for four weeks.
Change From Baseline in Mean Diurnal Intraocular Pressure (IOP) in the Study Eye at Week 4
Intraocular pressure (IOP) was measured in the study eye at baseline and Week 4. IOP is a measurement of the fluid pressure inside the eye. A negative number change from baseline indicates a reduction in IOP (improvement).
Time frame: Baseline, Week 4
| Milestone | Combigan® | Alphagan® and Timolol Concurrent |
|---|---|---|
| Started | 120 | 118 |
| Completed | 115 | 109 |
| Not completed | 5 | 9 |
Intraocular pressure (IOP) was measured in the study eye at baseline and Week 4. IOP is a measurement of the fluid pressure inside the eye. A negative number change from baseline indicates a reduction in IOP (improvement).
| mm Hg | Combigan® | Alphagan® and Timolol Concurrent |
|---|---|---|
| Baseline | 25.07 ± 3.737 | 24.53 ± 2.926 |
| Change from baseline at Week 4 | -6.21 ± 3.550 | -5.70 ± 3.469 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Combigan® | — | 1/120 (0.8%) | 0/120 (0%) |
| Alphagan® and Timolol Concurrent | — | 1/116 (0.9%) | 0/116 (0%) |
| Event | Combigan® | Alphagan® and Timolol Concurrent |
|---|---|---|
| VIth nerve paralysisNervous system disorders | 0/120 | 1/116 |
| Sudden hearing lossEar and labyrinth disorders | 1/120 | 0/116 |
| Age Continuous(Years) | Combigan® | Alphagan® and Timolol Concurrent | Total |
|---|---|---|---|
| Mean | 46.2 ± 15.18 | 48.2 ± 15.57 | 47.2 ± 15.38 |
| Sex: Female, Male(Participants) | Combigan® | Alphagan® and Timolol Concurrent | Total |
|---|---|---|---|
| Female | 48 | 55 | 103 |
| Male | 72 | 63 | 135 |
The record gives a start of Oct 2010, a primary completion of Sep 2011 and a completion of Sep 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2012, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Brimonidine · Timolol